01—Abstract
Summary
Summary of the 10-K filed February 19, 2025. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported fiscal 2024 total revenue of $4.05 billiona, down from $4.13 billion in fiscal 2023, a decrease of $79.4 million, or 1.9%, driven mainly by lower volume in its DSA business amid more cautious biopharmaceutical client spending.
Operating income fell to $227.3 millionb (5.6% operating margin) from $617.3 million (14.9%), reflecting a $215.0 million goodwill impairment in the Biologics Solutions reporting unit, restructuring charges of $107.0 million, and a $27 million inventory charge tied to the non-human primate investigations. Net income available to common shareholders dropped to $10.3 million, or $0.20 per diluted share, from $474.6 million, or $9.22 per diluted share, in 2023. Cash flow from operations was $734.6 million, and the company ended the year with $2.2 billion of debt and finance leases.
Management expects restructuring actions to yield approximately $225 millionc of annualized cost savings and plans to close or consolidate about 15 additional sites over the next two years. The company repurchased $100.7 million of stock in 2024, had $899.3 million remaining under its authorization, and intends to repurchase about $350 million in 2025. The Credit Facility was reduced from $3.0 billion to $2.0 billion and extended to December 2029.
The filing also highlights significant legal and regulatory exposure. U.S. DOJ and USFWS investigations into non-human primate shipments from Cambodia remain ongoing, with a parallel SEC inquiry, and a putative securities class action was dismissed in July 2024 and is on appeal.
Two derivative lawsuits are stayed pending that appeal. The company also disclosed a January 2025 CDMO client complete response letter and an FDA Form 483 at a Company facility, and noted that the NIH's February 7, 2025 indirect-cost policy has been temporarily stayed.
02—Key points
Key Highlights
- Revenue declined 1.9% to $4.05 billion in 2024, with DSA revenue down 6.3% to $2.45 billion on lower study volumes, while RMS grew 4.7% and Manufacturing grew 6.6%.
- Operating income fell to $227.3 million from $617.3 million, with operating margin of 5.6% versus 14.9% a year earlier.
- A $215.0 million goodwill impairment in the Biologics Solutions reporting unit followed a loss of key customers and a reduced long-range financial outlook.
- Net income available to common shareholders was $10.3 million ($0.20 diluted EPS), compared with $474.6 million ($9.22 diluted EPS) in 2023; the effective tax rate rose to 72.8%.
- Restructuring charges of $107.0 million are expected to deliver about $225 million of annualized cost savings, and about 15 additional sites are expected to be closed or consolidated over two years.
- Total debt and finance leases were $2.2 billion at year-end; operating cash flow was $734.6 million; the Credit Facility was reduced to $2.0 billion and extended to December 2029.
- Ongoing DOJ, USFWS and SEC investigations into Cambodia-sourced non-human primate shipments, plus shareholder litigation, remain unresolved, with the company unable to predict outcomes or potential penalties.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 19, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $4.05B$4.13B | −1.9% |
| SG&A Expenses | $751.00M$747.86M | +0.4% |
| Operating Income | $227.35M$617.26M | −63.2% |
| Net Income | $10.30M$474.62M | −97.8% |
| EPS (Basic) | $0.20$9.27 | −97.8% |
| EPS (Diluted) | $0.20$9.22 | −97.8% |
| Shares Outstanding (Basic) | 51.38M51.23M | +0.3% |
| Shares Outstanding (Diluted) | 51.63M51.45M | +0.3% |
05—Questions
Frequently Asked Questions
Why did Charles River's operating income fall so sharply in 2024?
Operating income dropped to $227.3 million from $617.3 million mainly because of lower DSA revenue, the $215.0 million goodwill impairment in Biologics Solutions, $107.0 million of restructuring charges, and a $27 million inventory charge tied to the non-human primate investigations.
What is the company doing to improve profitability?
Management is right-sizing its infrastructure, reducing staffing, consolidating facilities (planning to close or consolidate about 15 more sites over two years), and pursuing procurement and global business services savings. These actions are expected to yield approximately $225 million of annualized cost savings, of which about $100 million impacted fiscal 2024.
What legal risks could affect investors?
The company is cooperating with DOJ and USFWS investigations and a civil investigation into Cambodia-sourced non-human primate shipments, and with an SEC inquiry. A securities class action was dismissed in July 2024 and is on appeal, and two derivative lawsuits are stayed. The company cannot predict the timing, outcome, or possible fines, penalties or liabilities.
How is the company managing its capital and shareholder returns?
The company repurchased $100.7 million of stock in 2024 and had $899.3 million remaining under its authorization at year-end, with plans to repurchase about $350 million in 2025. It ended 2024 with $2.2 billion of debt and finance leases and reduced its revolving Credit Facility commitment from $3.0 billion to $2.0 billion, extending maturity to December 2029. The company does not pay cash dividends.
What was the outlook for the Biologics Solutions and CDMO business?
In December 2024, Biologics experienced the loss of certain key customers, which reduced its long-range financial outlook and triggered the goodwill impairment. The company expects lower revenue from commercial clients to affect its CDMO business in 2025, and in January 2025 a CDMO client disclosed FDA actions tied to inspections at a Company facility.
06—Continue